Vijaya Diagnostic Centre Ltd

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - The company funded the PH Diagnostics acquisition (₹147.50 crores) entirely through existing cash reserves. - Post-acquisition and dividend payment, the cash reserve stands at ₹158 crores. - The strong cash position and healthy balance sheet are highlighted as supporting future expansion. - No indications were given about raising additional capital via equity or debt at this time.

- The company continues to expand into new geographies following a well-thought-out expansion strategy. - Recent significant acquisition: PH Diagnostics in Pune for Rs.147.5 crores, fully funded from existing cash reserves. - The company is close to reaching 150 centers across 23 cities and 5 states. - New hub centers recently launched at Mahbubnagar and Gulbarga as part of Tier-2 city and adjacent geography expansion. - Additional two spokes added in Hyderabad network in the recent year. - Plans to open 12 to 15 centers annually remain intact, although some may spill over to the next financial year due to delays. - Expect increased CAPEX in Pune region with 2-3 hubs expected after acquisition integration. - In Kolkata, gradual, organic growth with 1 hub opening every two quarters; East India expansion continues at a measured pace. - The company is focusing on integrating PH's operations fully in the next two quarters, including front-end and back-end processes.

- The company expects a 14% to 15% growth primarily driven by volume growth (around 15% test volume growth). - Non-COVID revenue grew 17% YoY, with 18% volume growth including PH acquisition impact. - Volume growth is driven by both existing and new centers across geographies including Hyderabad, Pune, Kolkata, and Tier-2/ Tier-3 cities. - Hyderabad remains a key growth market expected to sustain high double-digit growth for the next 2-3 years. - The contribution from Hyderabad, currently ~80%, is expected to reduce to approximately 70-75% as other markets like Andhra, Pune, and Eastern India grow. - PH Pune acquisition (~Rs.42 crores revenue in FY23) is expected to grow further and contribute to revenue scaling. - The company plans to continue adding 12-15 centers annually, with expansion focused on existing and adjacent geographies. - Price hikes are limited (~1-1.5% annually); growth is volume-driven rather than price-driven.

- Vijaya Diagnostic Centre expects overall revenue growth of around 15% driven mainly by volume growth across geographies including Hyderabad, Pune, Tier-2 and Tier-3 cities, and East India. - PH Diagnostics acquisition in Pune is expected to contribute incremental revenue with growth potential beyond FY24. - EBITDA margins are expected to remain healthy around 39-40%, supported by operational efficiencies and integrated business model. - Price increases are minimal (~1-1.5%) and earnings growth is volume-led. - Hyderabad, the largest market (~80% revenue currently), will sustain double-digit growth for next 2-3 years with focus also shifting to Pune and East India. - Expansion strategy includes opening 12-15 new centers annually with hubs in Pune and Kolkata to ramp up, supporting long-term growth. - Solid cash reserves (Rs.158 crores post-acquisition) support organic and inorganic expansion. - Early break-even hubs (e.g., Kolkata) and new markets (Gulbarga) show promising ramp-up for profit contribution. - EPS growth expected to follow steady revenue and margin expansion over next 3-5 years.

- The transcript does not explicitly mention current or expected orderbook or pending orders. - Focus is on expansion plans including hubs and spokes, especially in Hyderabad and Pune. - 15 centers are planned to open annually, though some may spill over to the next financial year due to delays. - PH Diagnostics acquisition in Pune is fully integrated and expected to contribute to growth. - The company is expanding steadily in Tier-2 and adjacent geographies with hubs already opened in Mahbubnagar and Gulbarga. - Management emphasizes a careful, strategic expansion rather than rapid scaling. - No specific figures about orderbook or pending orders are disclosed in this call.